An FDA advisory panel unanimously gave a green light on Monday to the Alzheimer’s disease treatment donanemab for use during early stages of the disease.
June 11, 2024 –
The move makes it likely that the FDA will fully approve this monoclonal antibody drug. Donanemab targets the buildup of plaques in the brain that are an indicator of the severe form of dementia. The FDA had been expected to consider approving donanemab earlier this year as part of its fast track program. However, it delayed the decision and instead sought input during apublished last year suggested that the treatment could slow progression of the disease by a matter of months. This was based on people’s performance on tests that measure abilities related to cognition and to daily living skills, such as driving and managing finances.
Ultimately, advisors agreed that donanemab is safe and that the treatment’s benefits outweigh the risks.suggests the out-of-pocket annual cost of regularly getting donanemab infusions would be about $6,600 for people on Medicare. If fully approved, donanemab would join another recently approved monoclonal antibody treatment for Alzheimer’s disease called lecanemab. This drug also targets plaques and was approved by the FDA in July 2023.“A future with more approved Alzheimer’s treatments is a tremendous advancement for people eligible for these drugs.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA panel recommends approval of a blood test for colon cancerReuters
Read more »
Police response to Maine mass shooting gets deeper scrutiny from independent panelAn independent commission investigating a mass shooting in Maine plans to hear more testimony from law enforcement sources on communications and coordination problems.
Read more »
Police response to Maine mass shooting gets deeper scrutiny from independent panelAn independent commission investigating a mass shooting in Maine plans to hear more testimony from law enforcement sources on communications and coordination problems
Read more »
Police response to Maine mass shooting gets deeper scrutiny from independent panelAn independent commission investigating a mass shooting in Maine plans to hear more testimony from law enforcement sources on communications and coordination problems. The panel’s chair said last week that commissioners intend to address some of the “disturbing allegations” contained in a Portland police after-action report.
Read more »
Police response to Maine mass shooting gets deeper scrutiny from independent panelAn independent commission investigating a mass shooting in Maine plans to hear more testimony from law enforcement sources on communications and coordination problems.
Read more »
What to know about the blood test to detect colon cancer recommended by an FDA panelThe test's maker said the FDA will likely decide on approval later this year.
Read more »